4 results
The key objective of this study is to assess next-day residual effects of MK-4305 (20 and 40 mg) via driving performance after 1 day of dosing and after 8 days of dosing.
To investigate if antiplatelet therapy consisting of ticagrelor plus ASA is superior to clopidogrel plus ASA in preventing ischaemic brain lesions occurring as a result of CAS assessed on magnetic resonance imaging (MRI).
Primary objective: To evaluate the safety and tolerability of GSK1795091 when administered in combination with either GSK3174998, GSK3359609, orpembrolizumab.Secondary objectives: * To evaluate the antitumor activity of GSK1795091 when administered…
Primary ObjectiveThe primary objective of the study is to evaluate the effect of lemborexant 2.5, 5, and 10 mg compared to placebo on standard deviation of lateral position (SDLP) during an on-road driving test in the morning following a single dose…